You just read:

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

News provided by

DelMar Pharmaceuticals, Inc.

Nov 20, 2018, 05:30 ET